Zevra Therapeutics Inc
ZVRA
Get informed when a big investor buys or sells
+ FollowMarket Cap$799.24M
Close$
$-10.42
174.5% downside
Current Fair Value
174.5% downsideOvervalued by 174.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $799.24 Million |
|---|---|
| Enterprise Value | $725.14 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $1.4 |
| Beta | 0.89 |
| Outstanding Shares | 58,405,955 |
Return
| Return on Equity | 59.94% |
|---|---|
| Return on Assets | 44.28% |
| Return on Invested Capital | -3.06% |
Valuation & Multiples
| P/E Ratio | 6.2 |
|---|---|
| PEG | -0.47 |
| Price to Sales | 6.99 |
| Price to Book Ratio | 4.66 |
| Enterprise Value to Revenue | 5.93 |
| Enterprise Value to EBIT | -102.33 |
| Enterprise Value to Net Income | 5 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$31.96 M
Average shareholder expectationNext Earnings Call
Expected Date
August 11, 2026
EPS Estimate
$0.08
Average shareholder expectationRevenue Estimate
$33.89 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.9244▲ 127.69% |
|---|---|
| Total Calls | 1,126,300▼ 39.50% |
| Total Puts | 2,167,500▲ 79.82% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 74.70%▲ 6.52% |
|---|---|
| Total Invested | $384.58M▲ 12.52% |
| Investors Holding | 158▼ 11.00% |
ESG Score
No data
About Zevra Therapeutics Inc
24 employees
CEO: Travis Mickle KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its...